UltraGreenTranslation site

In today's era of rapid advancements in medical technology, precision surgery and intelligent healthcare have become pivotal trends across the global medical industry. As the global leader in fluorescence-guided surgery (FGS), UltraGreen.ai Limited (hereinafter referred to as “UltraGreen”) is redefining surgical precision and patient care standards through its vertically integrated AI tools and data-driven fluorescence imaging solutions.

I. Company Overview: From Technological Breakthroughs to Global Expansion

UltraGreen, founded in 2021 and headquartered in Singapore, is a company specializing in Fluorescence-Guided Surgery (FGS) andPrecision MedicineUltraGreen is a high-tech enterprise specializing in surgical navigation solutions. Guided by the vision of “making premium medical outcomes the global standard,” the company integrates AI algorithms, fluorescence imaging technology, and cloud computing platforms to provide surgeons with real-time, high-precision surgical navigation support.In November 2025, UltraGreen formally submitted its prospectus to the Singapore Exchange (SGX), planning to accelerate global expansion through IPO financing. This marks its transformation from a technology-driven startup to an industry leader.

The company's core team comprises leading experts in medical imaging, AI algorithms, and clinical medicine. Founder Ravi Sajwan has spearheaded multiple innovative projects in water treatment and energy sectors, bringing cross-industry experience that provides a unique perspective for UltraGreen's technology integration and commercialization strategy. Currently, UltraGreen has established multiple R&D centers globally and collaborates with several top European medical institutions to conduct clinical trials, forming a closed-loop ecosystem integrating technology, clinical practice, and commercialization.

II. Products and Services: Three Core Modules Building an Intelligent Surgical Ecosystem

UltraGreen's product portfolio centers around three key stages—“fluorescence imaging, real-time analysis, and cloud-based management”—forming a comprehensive solution covering the entire surgical workflow:

1. Fluorescence Imaging System (IC-Flow)
   As the core hardware of FGS, IC-Flow employs a high-sensitivity CMOS sensor and multispectral imaging technology to capture real-time distribution signals of fluorescent agents like indocyanine green (ICG) with micrometer-level resolution. Its innovative “support-free printing” process (similar to the support-free structures in Ultra SLM metal 3D printing) optimizes the device's lightweight design, facilitating flexible deployment in operating rooms.Currently, IC-Flow has obtained both EU CE certification and U.S. FDA Breakthrough Device designation, establishing itself as the preferred tool for high-precision surgeries including hepatobiliary procedures and tumor resection.
2. AI-Assisted Analysis Software (UltraLinq)
   UltraLinq utilizes deep learning algorithms to automatically identify key anatomical structures (such as blood vessels and tumor margins) within fluorescent signals and generate three-dimensional reconstruction models. Its “dynamic path planning” feature adjusts surgical incision placement based on real-time imaging, reducing procedure time by over 30%.Clinical data from 2025 indicates that liver resection surgeries using UltraLinq reduced blood loss by 42% and decreased postoperative complication rates by 28%.
3. Cloud-Based Medical Imaging Platform
   Through a blockchain-encrypted cloud platform, UltraGreen enables cross-institutional sharing of surgical imaging and remote consultations. Physicians can upload fluorescence data captured by IC-Flow, whereupon the AI system automatically generates structured reports and matches them against a global database of similar cases for reference. Currently, the platform has integrated over 50 international medical institutions, processing more than 10TB of surgical imaging data daily.

III. Core Technology: Cross-Boundary Integration of AI and Fluorescence Imaging

UltraGreen's technological barriers manifest across three key dimensions:

1. Multimodal Data Fusion Algorithm
   The company's proprietary “FusionNet” algorithm simultaneously processes fluorescence signals, visible light images, and patients“ preoperative CT/MRI data. It achieves precise anatomical structure alignment through cross-modal feature registration technology. This algorithm received the ”Best Clinical Application Award" at the 2025 International Conference on Medical Image Computing and Computer-Assisted Intervention (MICCAI), demonstrating a 171% improvement in recognition accuracy compared to traditional methods.
2. Low-Dose Fluorescent Agent Optimization Technology
   To address the rapid metabolism and signal decay of ICG in vivo, UltraGreen has developed a nano-encapsulation technology that extends the fluorescent dye's half-life to 2.3 times that of conventional products while reducing the required dosage by 30%, significantly lowering the risk of allergic reactions.
3. Edge Computing and 5G Real-Time Transmission
   To address network latency in operating rooms, UltraGreen has embedded edge computing modules within its IC-Flow devices to enable localized AI analysis. Combined with a 5G private network, surgical imagery can be transmitted to the cloud in as little as 50 milliseconds, meeting the real-time requirements for remote surgical guidance.

IV. Primary Users: Comprehensive Coverage from Top-Tier Hospitals to Primary Care Facilities

UltraGreen's user base exhibits a pyramid-shaped distribution:

• Top Floor: International Premier Medical Center
  Hospitals such as Heidelberg University Hospital in Germany and Johns Hopkins Hospital in the United States utilize the UltraGreen system for complex tumor resection and organ transplant surgeries. By 2025, pancreatic cancer surgeries performed at Heidelberg Hospital using IC-Flow achieved a five-year survival rate 11 percentage points higher than traditional methods.
• Mid-level: Regional General Hospital
  Through its “equipment leasing + pay-per-procedure” model, UltraGreen promotes standardized surgical packages to secondary hospitals in Southeast Asia and the Middle East. For instance, after introducing UltraLinq, Chulalongkorn Hospital in Thailand reduced the average length of stay for hepatobiliary surgeries from 7.2 days to 4.5 days.
• Frontline: Mobile Healthcare and Emergency Response Scenarios
  For resource-scarce environments such as battlefields and disaster zones, UltraGreen has developed a portable fluorescence imager compatible with smartphones. During the 2025 flood relief efforts in Cambodia, this device enabled medical teams to successfully perform multiple trauma suturing procedures in the field.

V. Development Prospects: Three Major Trends Driving a Trillion-Dollar Market

1. Policy dividends are being released
   Multiple countries worldwide have incorporated precision medicine into their national strategies. For instance, China's “14th Five-Year Plan for Medical Equipment Industry Development” explicitly supports the R&D of fluorescence guidance systems, with the domestic FGS market projected to exceed 8 billion yuan by 2027.
2. Technology-Driven Cost Reduction and Popularization
   UltraGreen plans to reduce the unit price of IC-Flow from the current $500,000 to under $300,000 by optimizing its supply chain—such as adopting Meng 3D's metal 3D printing technology to lower equipment manufacturing costs—accelerating its penetration into developing countries.
3. Ecological Synergy Expansion
   The company is collaborating with pharmaceutical firms to develop fluorescently labeled targeted drugs, integrating AI navigation modules into robotic surgical systems to build a closed-loop “drug-device-service” ecosystem. According to Morgan Stanley projections, the global FGS-related market is expected to reach $22 billion by 2030, with UltraGreen poised to capture over 30% market share.

Conclusion: The “Ultra Era” of Intelligent Healthcare”

From the microscopic world of fluorescence imaging to the macro-level decision-making of AI algorithms, UltraGreen is redefining surgical boundaries through technological innovation. As its IPO progresses, this young enterprise will gain robust capital backing to propel FGS technology from a “high-end option” to a “universal necessity.” In the vast expanse of precision medicine, UltraGreen has set sail toward an even broader future.